New hope for teens: schizophrenia drug safety trial completed

NCT ID NCT02411695

Completed Symptom relief Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested the safety and how the body processes the drug brexpiprazole in 43 teenagers aged 13-17 with schizophrenia. Researchers monitored side effects and changes in vital signs over 17 days. The goal was to find a safe dose for future studies, not to measure how well it treats symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Study site

Culver City, California, 90230, United States
Study site

Orange, California, 92858, United States
Study site

Washington D.C., District of Columbia, 20016, United States
Study site

Atlanta, Georgia, 30331, United States
Study site

Marlton, New Jersey, 08053, United States
Study site

Cincinnati, Ohio, 45219, United States
Study site

Cleveland, Ohio, 44106, United States
Study site

The Woodlands, Texas, 77381, United States
Study site

Orem, Utah, 84058, United States
Study site

Little Rock, Arkansas, 72211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.